Veterinary Medicines

Fatroximin Intrauterine Foam 0,75 g/100 g Aerozol

Authorised
  • Rifaximin
Download as PDF

Product identification

Medicine name:
Fatroximin Intrauterine Foam 0,75 g/100 g Aerozol
Active substance:
  • Rifaximin
Target species:
  • Cattle
  • Horse
Route of administration:
  • Vaginal use
  • Intrauterine use

Product details

Active substance and strength:
  • Rifaximin
    0.75
    gram(s)
    /
    100.00
    gram(s)
Pharmaceutical form:
This information is not available for this product.
Withdrawal period by route of administration:
  • Vaginal use
    • Cattle
      • Milk
        0
        day
      • Meat and offal
        0
        day
    • Horse
      • All relevant tissues
        no withdrawal period
  • Intrauterine use
    • Cattle
      • Meat and offal
        0
        day
      • Milk
        0
        day
    • Horse
      • All relevant tissues
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QG51AA06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Poland
Available in:
  • Poland
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • Office For Registration Of Medicinal Products Medical Devices And Biocidal Products
Authorisation number:
  • 1020
Date of authorisation status change:

Documents

Labelling

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 26/04/2022
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Polish (PDF)
Published on: 26/04/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."